{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T09:02:09Z","timestamp":1724662929244},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This case reveals a novel presentation of drug rash with eosinophilia and systemic symptoms syndrome that mimics a lymphoproliferative disorder. The heterogeneous clinical presentation of drug rash with eosinophilia and systemic symptoms syndrome gives rise to a broad differential diagnosis that includes a multitude of infectious, inflammatory, and autoimmune conditions. This patient was diagnosed with drug rash with eosinophilia and systemic symptoms syndrome 4\u00a0weeks after starting sulfasalazine and 5\u00a0weeks after starting hydroxychloroquine for rheumatoid arthritis. Both of these medications have been shown to cause drug rash with eosinophilia and systemic symptoms syndrome, albeit more rarely in the context of hydroxychloroquine. This patient\u2019s history, physical examination, and workup illuminate a case of drug rash with eosinophilia and systemic symptoms syndrome that masquerades as a lymphoproliferative disorder despite its adherence to the RegiSCAR criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 22-year-old African-American female with an atopic history and rheumatoid arthritis presented for evaluation of a rash, unremitting fevers, and syncope. She was found to have drug rash with eosinophilia and systemic symptoms syndrome. A syncope workup was unremarkable. Computed tomography of the chest\/abdomen\/pelvis confirmed extensive lymphadenopathy and revealed a small right pleural effusion (Fig. 5). These imaging findings accompanied by fevers and a rash in the setting of eosinophilia, leukocytosis, and transaminitis led to the clinical suspicion for drug rash with eosinophilia and systemic symptoms syndrome. Steroids were subsequently initiated. Broad-spectrum antibiotic therapy was implemented to cover for possible skin\/soft tissue infection due to initial paradoxical worsening after discontinuation of the culprit drugs. Lymph node biopsy ruled out a lymphoproliferative disorder and instead demonstrated necrotizing lymphadenitis. An extensive infectious and autoimmune workup was noncontributory. Clinical improvement was visualized, antibiotics were discontinued, and she was discharged on a steroid taper.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case reflects how drug rash with eosinophilia and systemic symptoms syndrome can masquerade as a lymphoproliferative disorder. Additionally, it highlights the extent to which rapid identification and treatment optimized the patient\u2019s outcome. It calls into question how immunogenetics may factor into a patient\u2019s susceptibility to acquire drug rash with eosinophilia and systemic symptoms syndrome. This case is unique because of the early onset of visceral organ involvement, the type of internal organ involvement, the hematopoietic features, and the lymphadenopathy associated with a disease-modifying antirheumatic drug.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-022-03526-0","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T23:02:47Z","timestamp":1662332567000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug rash with eosinophilia and systemic symptoms syndrome masquerading as a lymphoproliferative disorder in a young adult on immunosuppressive therapy for rheumatoid arthritis: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Elise","family":"Hyser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"9","key":"3526_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/archdermatol.2012.1079","volume":"148","author":"H Lee","year":"2012","unstructured":"Lee H, Walsh S, Creamer D. Initial presentation of DRESS: often misdiagnosed as infections. Arch Dermatol. 2012;148(9):1085\u20137. https:\/\/doi.org\/10.1001\/archdermatol.2012.1079.","journal-title":"Arch Dermatol"},{"issue":"6","key":"3526_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","volume":"156","author":"E Nguyen","year":"2020","unstructured":"Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of cyclosporine for the treatment of DRESS syndrome. JAMA Dermatol. 2020;156(6):704\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0048.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"3526_CR3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"S Kardaun","year":"2013","unstructured":"Kardaun S, Sekula P, Valeyrie-Allanore L, et\u00a0al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380. https:\/\/doi.org\/10.1111\/bjd.12501.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3526_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4168\/aair.2014.6.3.216","volume":"6","author":"DH Kim","year":"2014","unstructured":"Kim DH, Young K. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Immunol Res. 2014;6(3):216\u201321.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"3526_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/jamadermatol.2021.5390","volume":"158","author":"A Creadore","year":"2022","unstructured":"Creadore A, Desai S, Alloo A, et\u00a0al. Clinical characteristics, disease course, and outcomes of patients with acute generalized exanthematous pustulosis in the US. JAMA Dermatol. 2022;158(2):176\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5390.","journal-title":"JAMA Dermatol"},{"key":"3526_CR6","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"G Tsokos","year":"2011","unstructured":"Tsokos G. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110\u201321. https:\/\/doi.org\/10.1056\/NEJMra1100359.","journal-title":"N Engl J Med"},{"issue":"21","key":"3526_CR7","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064\u201373. https:\/\/doi.org\/10.1182\/blood-2008-10-184168.","journal-title":"Blood"},{"issue":"9","key":"3526_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","volume":"126","author":"A Klion","year":"2015","unstructured":"Klion A. How I treat hypereosinophilic syndromes. Blood. 2015;126(9):1069\u201377. https:\/\/doi.org\/10.1182\/blood-2014-11-551614.","journal-title":"Blood"},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/s41598-022-06757-9","volume":"12","author":"AR Manasra","year":"2022","unstructured":"Manasra AR, Al-Domaidat H, Aideh MA, et\u00a0al. Kikuchi\u2013Fujimoto disease in the Eastern Mediterranean zone. Sci Rep. 2022;12:2703.","journal-title":"Sci Rep"},{"issue":"5","key":"3526_CR10","doi-asserted-by":"publisher","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","volume":"68","author":"Z Husain","year":"2013","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1-14.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"3526_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaad.2015.02.1130","volume":"72","author":"IC Lin","year":"2015","unstructured":"Lin IC, Yang HC, Strong C, et\u00a0al. Liver injury in patients with DRESS: a clinical study of 72 cases. J Am Acad Dermatol. 2015;72(6):984\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"3526_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fmed.2017.00179","volume":"4","author":"P Musette","year":"2017","unstructured":"Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front Med. 2017;4:179. https:\/\/doi.org\/10.3389\/fmed.2017.00179.","journal-title":"Front Med"},{"key":"3526_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13223-019-0340-7","volume":"15","author":"M Silva","year":"2019","unstructured":"Silva M, Santana MBR, Tosta BR, et\u00a0al. Variants in the IL-17 pathway genes are associated with atopic asthma and atopy markers in a South American population. Allergy Asthma Clin Immunol. 2019;15:28. https:\/\/doi.org\/10.1186\/s13223-019-0340-7.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3526_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13223-021-00535-4","volume":"17","author":"A Dhir","year":"2021","unstructured":"Dhir A, Kular H, Elzagallaai AA, et\u00a0al. DRESS induced by amoxicillin\u2013clavulanate in two pediatric patients confirmed by lymphocyte toxicity assay. Allergy Asthma Clin Immunol. 2021;17:37. https:\/\/doi.org\/10.1186\/s13223-021-00535-4.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3526_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","volume":"28","author":"A Sidoroff","year":"2001","unstructured":"Sidoroff A, Halevy S, Bavinck JN, et\u00a0al. Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern. J Cutan Pathol. 2001;28:113.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"3526_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.13683","volume":"173","author":"N Ortonne","year":"2015","unstructured":"Ortonne N, Valeyrie-Allanore L, Bastuji-Garin S, et\u00a0al. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. Br J Dermatol. 2015;173(1):50\u20138. https:\/\/doi.org\/10.1111\/bjd.13683.","journal-title":"Br J Dermatol"},{"key":"3526_CR17","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.4103\/0973-3698.272151","volume":"14","author":"KC Shanoj","year":"2019","unstructured":"Shanoj KC, Joseph S, Shenoy P. Drug reaction with eosinophilia and systemic symptoms syndrome. Indian J Rheumatol. 2019;14:S59-66.","journal-title":"Indian J Rheumatol"},{"issue":"4","key":"3526_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamadermatol.2013.1949","volume":"149","author":"EM Singer","year":"2013","unstructured":"Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol. 2013;149(4):494\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2013.1949.","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03526-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T15:14:39Z","timestamp":1701011679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03526-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}